At the American Society for Cell Biology (ASCB) Annual Meeting, the BioSciences Group of Fujitsu Computer Systems has announced an evaluation project with Whitehead Institute for Biomedical Research, focusing on high-throughput cell-based research.
As part of the project, Fujitsu will provide Whitehead with the CELLINJECTOR automated microinjection system to help develop efficient workflows for researchers currently working on cell-based assays.
Whitehead researchers will utilize CELLINJECTOR for a variety of research projects, including peptide expression and trafficking in stem cells, assessment of gene expression controls, and the study of cell-signaling cascades, among others.
According to Paul Matsudaira, director of Whitehead Institute-MIT BioImaging Center, "We are looking forward to promising results based on new techniques leveraging automated microinjection technologies."
"Our researchers envision broad utility of this kind of technology in developing efficient workflows for high-throughput cell-based research."
Dr. Michael J. McManus, vice president of Business Development for the BioSciences Group of Fujitsu Computer Systems, said, "The precision and automation of CELLINJECTOR vastly improves the efficiency and throughput of cell injections, easily performing thousands of successful injections per day compared to hundreds done manually."
"We are confident that high-throughput injection technologies such as CELLINJECTOR will help advance development of effective microinjection-based techniques across a wide spectrum of research areas, especially for cell types that are notoriously difficult to transfect."
The CELLINJECTOR system is a high-throughput, efficient, automated method for directly injecting a large number of cells.
Fujitsu claims that, CELLINJECTOR is computer-controlled, so operators do not need extensive injection training to perform efficient cellular injections.